A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients

Aljohara S Almeneessier,1,2 Nouf S Alballa,1 Budoor H Alsalman,1 Salih Aleissi,1 Awad H Olaish,1 Ahmed S BaHammam1 1Department of Medicine, College of Medicine, the University Sleep Disorders Center, Riyadh, Saudi Arabia; 2Family and Community Medicine Department, College of Medicine, King Saud Univ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Almeneessier AS, Alballa NS, Alsalman BH, Aleissi S, Olaish AH, BaHammam AS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	body mass index sleep quality daytime sleepiness Pittsburgh sleep quality index Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
Acceso en línea:	https://doaj.org/article/1ffa15374c6d4529a49fc1fbe3c2ca82
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ffa15374c6d4529a49fc1fbe3c2ca82
record_format	dspace
spelling	oai:doaj.org-article:1ffa15374c6d4529a49fc1fbe3c2ca822021-12-02T08:11:42ZA 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients1179-1608https://doaj.org/article/1ffa15374c6d4529a49fc1fbe3c2ca822019-10-01T00:00:00Zhttps://www.dovepress.com/a-10-year-longitudinal-observational-study-of-cataplexy-in-a-cohort-of-peer-reviewed-article-NSShttps://doaj.org/toc/1179-1608Aljohara S Almeneessier,1,2 Nouf S Alballa,1 Budoor H Alsalman,1 Salih Aleissi,1 Awad H Olaish,1 Ahmed S BaHammam1 1Department of Medicine, College of Medicine, the University Sleep Disorders Center, Riyadh, Saudi Arabia; 2Family and Community Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Ahmed S BaHammam; Aljohara S AlmeneessierSleep Disorders Center, College of Medicine, King Saud University, Box 225503, Riyadh 11324, Saudi ArabiaTel +966-11-467-9495Fax +966-11-467-9179Email ashammam2@gmail.com; aljoharas@yahoo.comPurpose: Narcolepsy type 1 (NT1) is thought to have a chronic persistent course. This study aimed to assess the natural course of cataplexy in patients with NT1 at 2, 6, and 10 years after stabilizing symptoms. Other secondary objectives included assessing sleep quality, body mass index (BMI), and comorbidities at recruitment and 10 years later.Patients and methods: Cataplexy symptoms, the Epworth sleepiness scale (ESS), sleep quality (assessed using the Pittsburgh sleep quality index [PSQI]), BMI, and comorbid conditions were prospectively monitored in 38 patients with NT1. The study sample comprised 38 patients with narcolepsy (males=27). The mean ages at disease onset and recruitment were 17.7 ± 5.6 years and 24.3 ± 8.6 years, respectively.Results: In 42% of the cohort, the anti-cataplectic medications were stopped at the end of the study without disturbing symptoms of cataplexy. Additionally, there was an apparent significant reduction in the frequency of cataplexy over time. The mean ESS score decreased by more than 4 points from 19.4 ± 2.9 to 15 ± 4.3 (p<0.001) while on the same pharmacotherapy. The number of patients with a PSQI score of <5 (indicating good sleep quality) increased from 6 (15.8%) to 15 (39.5%) (p=0.004). The BMI increased from 30 ± 5.1 to 33.3 ± 6 kg/m2 (p=0.001). No changes were documented in comorbidities.Conclusion: The findings suggest that the course of NT1 is not stable. Over a 10-year period, cataplexy symptoms improved or disappeared in a large proportion of patients, and there was an improvement in daytime sleepiness and nighttime sleep quality. More prospective studies that repeatedly monitor CSF-HCRT are needed to confirm the current findings.Keywords: body mass index, sleep quality, daytime sleepiness, Pittsburgh Sleep Quality IndexAlmeneessier ASAlballa NSAlsalman BHAleissi SOlaish AHBaHammam ASDove Medical Pressarticlebody mass indexsleep qualitydaytime sleepinessPittsburgh sleep quality indexPsychiatryRC435-571Neurophysiology and neuropsychologyQP351-495ENNature and Science of Sleep, Vol Volume 11, Pp 231-239 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	body mass index sleep quality daytime sleepiness Pittsburgh sleep quality index Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495
spellingShingle	body mass index sleep quality daytime sleepiness Pittsburgh sleep quality index Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495 Almeneessier AS Alballa NS Alsalman BH Aleissi S Olaish AH BaHammam AS A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
description	Aljohara S Almeneessier,1,2 Nouf S Alballa,1 Budoor H Alsalman,1 Salih Aleissi,1 Awad H Olaish,1 Ahmed S BaHammam1 1Department of Medicine, College of Medicine, the University Sleep Disorders Center, Riyadh, Saudi Arabia; 2Family and Community Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Ahmed S BaHammam; Aljohara S AlmeneessierSleep Disorders Center, College of Medicine, King Saud University, Box 225503, Riyadh 11324, Saudi ArabiaTel +966-11-467-9495Fax +966-11-467-9179Email ashammam2@gmail.com; aljoharas@yahoo.comPurpose: Narcolepsy type 1 (NT1) is thought to have a chronic persistent course. This study aimed to assess the natural course of cataplexy in patients with NT1 at 2, 6, and 10 years after stabilizing symptoms. Other secondary objectives included assessing sleep quality, body mass index (BMI), and comorbidities at recruitment and 10 years later.Patients and methods: Cataplexy symptoms, the Epworth sleepiness scale (ESS), sleep quality (assessed using the Pittsburgh sleep quality index [PSQI]), BMI, and comorbid conditions were prospectively monitored in 38 patients with NT1. The study sample comprised 38 patients with narcolepsy (males=27). The mean ages at disease onset and recruitment were 17.7 ± 5.6 years and 24.3 ± 8.6 years, respectively.Results: In 42% of the cohort, the anti-cataplectic medications were stopped at the end of the study without disturbing symptoms of cataplexy. Additionally, there was an apparent significant reduction in the frequency of cataplexy over time. The mean ESS score decreased by more than 4 points from 19.4 ± 2.9 to 15 ± 4.3 (p<0.001) while on the same pharmacotherapy. The number of patients with a PSQI score of <5 (indicating good sleep quality) increased from 6 (15.8%) to 15 (39.5%) (p=0.004). The BMI increased from 30 ± 5.1 to 33.3 ± 6 kg/m2 (p=0.001). No changes were documented in comorbidities.Conclusion: The findings suggest that the course of NT1 is not stable. Over a 10-year period, cataplexy symptoms improved or disappeared in a large proportion of patients, and there was an improvement in daytime sleepiness and nighttime sleep quality. More prospective studies that repeatedly monitor CSF-HCRT are needed to confirm the current findings.Keywords: body mass index, sleep quality, daytime sleepiness, Pittsburgh Sleep Quality Index
format	article
author	Almeneessier AS Alballa NS Alsalman BH Aleissi S Olaish AH BaHammam AS
author_facet	Almeneessier AS Alballa NS Alsalman BH Aleissi S Olaish AH BaHammam AS
author_sort	Almeneessier AS
title	A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
title_short	A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
title_full	A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
title_fullStr	A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
title_full_unstemmed	A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients
title_sort	10-year longitudinal observational study of cataplexy in a cohort of narcolepsy type 1 patients
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/1ffa15374c6d4529a49fc1fbe3c2ca82
work_keys_str_mv	AT almeneessieras a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT alballans a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT alsalmanbh a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT aleissis a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT olaishah a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT bahammamas a10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT almeneessieras 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT alballans 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT alsalmanbh 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT aleissis 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT olaishah 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients AT bahammamas 10yearlongitudinalobservationalstudyofcataplexyinacohortofnarcolepsytype1patients
_version_	1718398589517955072

A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients

Ejemplares similares